Quick Answer
Vaxcyte, Inc. reported Net Income of -$766.63 million for fiscal year 2025.
Vaxcyte, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$766.63M -65.2% |
-$463.93M -15.3% |
-$402.27M -80.0% |
-$223.49M -123.3% |
-$100.08M -12.2% |
-$89.22M -77.5% |
| Diluted EPS | -$5.63 -48.2% |
-$3.80 +8.2% |
-$4.14 -20.3% |
-$3.44 -78.2% |
-$1.93 +36.1% |
-$3.02 |
| Total Assets | $3.00B -14.5% |
$3.51B +149.4% |
$1.41B +39.9% |
$1.01B +210.2% |
$324.34M -17.4% |
$392.83M +497.9% |
| Cash and Equivalents | $173.96M -55.2% |
$387.88M -2.4% |
$397.45M -52.4% |
$834.66M +1109.9% |
$68.98M -82.1% |
$386.20M +554.8% |
| Stockholders Equity | $2.69B -18.8% |
$3.31B +166.5% |
$1.24B +30.1% |
$953.61M +235.8% |
$284.02M -17.9% |
$345.84M +425.1% |
| R&D Expense | $794.31M +66.6% |
$476.64M +43.4% |
$332.34M +96.1% |
$169.45M +116.1% |
$78.41M +6.6% |
$73.56M +61.3% |
| Operating Income | -$923.67M -62.2% |
-$569.55M -21.7% |
-$468.04M -101.5% |
-$232.26M -124.0% |
-$103.67M -15.7% |
-$89.58M -65.4% |
| Shares Outstanding | 131.06M +4.9% |
124.89M +31.0% |
95.36M +20.0% |
79.47M +49.9% |
53.03M +3.8% |
51.07M +1157.9% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$212.83M | -106.4% | -27.8% |
| Diluted EPS | September 30, 2025 | -$1.56 | -88.0% | -27.9% |
| Total Assets | September 30, 2025 | $3.17B | -10.9% | -4.0% |
| Cash and Equivalents | September 30, 2025 | $281.08M | -73.2% | -8.4% |
| Stockholders Equity | September 30, 2025 | $2.89B | -15.4% | -5.8% |
| R&D Expense | September 30, 2025 | $209.93M | +79.5% | +8.1% |
| Operating Income | September 30, 2025 | -$242.38M | -73.2% | -7.1% |
| Shares Outstanding | September 30, 2025 | 130.03M | +4.5% | +0.2% |
- Vaxcyte, Inc. reported Net Income of -$766.63 million for fiscal year 2025.
- Vaxcyte, Inc. showed a decrease of -65.2% in Net Income compared to the prior fiscal year.
- Vaxcyte, Inc. reported Diluted EPS of $5.63 per share (loss) for fiscal year 2025.
- Vaxcyte, Inc. showed a decrease of -48.2% in Diluted EPS compared to the prior fiscal year.
- Vaxcyte, Inc. reported Total Assets of $3.00 billion for fiscal year 2025.
- Vaxcyte, Inc. showed a decrease of -14.5% in Total Assets compared to the prior fiscal year.
- Vaxcyte, Inc. reported Cash and Equivalents of $173.96 million for fiscal year 2025.
- Vaxcyte, Inc. showed a decrease of -55.2% in Cash and Equivalents compared to the prior fiscal year.
- Vaxcyte, Inc. reported Stockholders Equity of $2.69 billion for fiscal year 2025.
- Vaxcyte, Inc. showed a decrease of -18.8% in Stockholders Equity compared to the prior fiscal year.
- Vaxcyte, Inc. reported R&D Expense of $794.31 million for fiscal year 2025.
- Vaxcyte, Inc. showed an increase of +66.6% in R&D Expense compared to the prior fiscal year.
- Vaxcyte, Inc. reported Operating Income of -$923.67 million for fiscal year 2025.
- Vaxcyte, Inc. showed a decrease of -62.2% in Operating Income compared to the prior fiscal year.
- Vaxcyte, Inc. reported Shares Outstanding of 131.06 million shares for fiscal year 2025.
- Vaxcyte, Inc. showed an increase of +4.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: